Clinical Trial Update: Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 Infection [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing MF59-adjuvanted vs non-adjuvanted influenza vaccines in people with HIV-1 infection to evaluate immunogenicity, safety, and tolerabili…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• MF59-adjuvanted influenza vaccine (influenza vaccine adjuvanted with MF59)
• Non-adjuvanted influenza vaccine (influenza vaccine)

Snippet

Sponsor: Chiltern Pesquisa Clinica Ltda | Conditions: H1N1 Influenza Virus, Human Immunodeficiency Virus Type 1 (HIV-1) Infection | Phase 3 | Status: COMPLETED